Compare $INTI vs $MRKR | Chartloom

Compare

$INTI vs $MRKR

Inhibitor Therapeutics Inc · Marker Therapeutics Inc

INTI

Inhibitor Therapeutics Inc

MRKR

Marker Therapeutics Inc

Compare $INTI vs $MRKR

Comparing Inhibitor Therapeutics Inc and Marker Therapeutics Inc

INTIInhibitor Therapeutics Inc

MRKRMarker Therapeutics Inc

INTIInhibitor Therapeutics Inc

Market cap

$17M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

108.5%

52W performance

127.9%

FCF yield

-19.1%

MRKRMarker Therapeutics Inc

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.16x

Rev growth (TTM)

-46.2%

YTD performance

-36.9%

52W performance

-10.0%

FCF yield

-60.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INTI

MRKR

Detailed metrics comparison

INTI

Inhibitor Therapeutics Inc

MRKR

Marker Therapeutics Inc

Market Cap

INTI$17M

MRKR$16M

Enterprise Value

INTI$16M

MRKR$5M

Price

INTI$0.10

MRKR$0.97

P/E Ratio

INTIN/A

MRKRN/A

P/S Ratio

INTI4.25x

MRKR6.93x

EV/Sales

INTI4.12x

MRKR2.08x

EV/EBITDA

INTI1.61x

MRKR0.00x

P/B Ratio

INTI4,922.43x

MRKR1.44x

P/FCF Ratio

INTIN/A

MRKRN/A

EV/FCF

INTI-5.09x

MRKR-0.50x

PEG Ratio

INTIN/A

MRKRN/A

Forward P/E (NTM)

INTIN/A

MRKRN/A

Forward P/S (NTM)

INTIN/A

MRKR3.16x

Revenue (TTM)

INTI$0

MRKR$2M

Revenue Growth (YoY)

INTIN/A

MRKR-46.2%

Forward Rev Growth

INTI0.0%

MRKR375.8%

Gross Margin (TTM)

INTI20.9%

MRKR0.0%

Operating Margin (TTM)

INTI0.0%

MRKR0.0%

EBITDA Margin (TTM)

INTI0.0%

MRKR-284.3%

Net Margin (TTM)

INTI0.0%

MRKR-236.6%

FCF Margin (TTM)

INTIN/A

MRKR-417.6%

Net Income (TTM)

INTI$-3M

MRKR$-6M

FCF (TTM)

INTI$-3M

MRKR$-10M

EPS (TTM)

INTI$0.00

MRKR-$0.27

ROE (TTM)

INTI-33792.0%

MRKR-8086.0%

ROA (TTM)

INTI-12210.0%

MRKR-6705.0%

ROIC (TTM)

INTI-33792.0%

MRKR-8086.0%

Cash

INTI$516K

MRKR$11M

Debt

INTI$0

MRKR$0

Net Cash/Debt

INTI$516K

MRKR$11M

Current Ratio (TTM)

INTI3.36x

MRKR6.03x

Quick Ratio (TTM)

INTI2.95x

MRKR5.60x

Debt/Equity (TTM)

INTI0.00x

MRKR0.00x

Debt/Assets (TTM)

INTI0.0%

MRKR0.0%

Interest Coverage (TTM)

INTIN/A

MRKRN/A

Net Debt/EBITDA (TTM)

INTI0.00x

MRKR0.00x

Beta

INTI-0.79

MRKR1.59

52W Performance

INTI127.9%

MRKR-10.0%

YTD Performance

INTI108.5%

MRKR-36.9%

% from 52W High

INTI-21.0%

MRKR-60.5%

% from 52W Low

INTI180.0%

MRKR15.7%

Asset Turnover (TTM)

INTI0.50x

MRKR0.20x

FCF Yield (TTM)

INTI-19.1%

MRKR-60.2%

Earnings Yield (TTM)

INTI-15.9%

MRKR-34.1%

Dividend Yield (TTM)

INTIN/A

MRKRN/A

Rule of 40

INTI0.0

MRKR-463.8

EV/GP/RG

INTIN/A

MRKRN/A

Ticker research

View INTI research View MRKR research

Metric	INTI Inhibitor Therapeutics Inc	MRKR Marker Therapeutics Inc
Market & Valuation
Market Cap	$17M	$16M
Enterprise Value	$16M	$5M
Price	$0.10	$0.97
P/E Ratio	N/A	N/A
P/S Ratio	4.25x	6.93x
EV/Sales	4.12x	2.08x
EV/EBITDA	1.61x	0.00x
P/B Ratio	4,922.43x	1.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.09x	-0.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.16x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	-46.2%
Forward Rev Growth	0.0%	375.8%
Profitability
Gross Margin (TTM)	20.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-284.3%
Net Margin (TTM)	0.0%	-236.6%
FCF Margin (TTM)	N/A	-417.6%
Net Income (TTM)	$-3M	$-6M
FCF (TTM)	$-3M	$-10M
EPS (TTM)	$0.00	-$0.27
ROE (TTM)	-33792.0%	-8086.0%
ROA (TTM)	-12210.0%	-6705.0%
ROIC (TTM)	-33792.0%	-8086.0%
Financial Health
Cash	$516K	$11M
Debt	$0	$0
Net Cash/Debt	$516K	$11M
Current Ratio (TTM)	3.36x	6.03x
Quick Ratio (TTM)	2.95x	5.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.79	1.59
52W Performance	127.9%	-10.0%
YTD Performance	108.5%	-36.9%
% from 52W High	-21.0%	-60.5%
% from 52W Low	180.0%	15.7%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.20x
FCF Yield (TTM)	-19.1%	-60.2%
Earnings Yield (TTM)	-15.9%	-34.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-463.8
EV/GP/RG	N/A	N/A
Ticker research	View INTI research	View MRKR research

Valuation

P/S Ratio

INTI

4.25x

MRKR

6.93x

EV/FCF

INTI

-5.09x

MRKR

-0.50x

Growth & revenue

Revenue Growth TTM

MRKR

-46.2%

Forward Revenue Growth

MRKR

375.8%

INTI

0.0%

Profitability & performance

Gross Margin

INTI

20.9%

MRKR

0.0%

ROE

MRKR

-8086.0%

INTI

-33792.0%

FCF Yield %

INTI

-19.1%

MRKR

-60.2%

52-Week Performance

INTI

127.9%

MRKR

-10.0%

Detailed metrics comparison

INTI

Inhibitor Therapeutics Inc

MRKR

Marker Therapeutics Inc

Market Cap

INTI$17M

MRKR$16M

Enterprise Value

INTI$16M

MRKR$5M

Price

INTI$0.10

MRKR$0.97

P/E Ratio

INTIN/A

MRKRN/A

P/S Ratio

INTI4.25x

MRKR6.93x

EV/Sales

INTI4.12x

MRKR2.08x

EV/EBITDA

INTI1.61x

MRKR0.00x

P/B Ratio

INTI4,922.43x

MRKR1.44x

P/FCF Ratio

INTIN/A

MRKRN/A

EV/FCF

INTI-5.09x

MRKR-0.50x

PEG Ratio

INTIN/A

MRKRN/A

Forward P/E (NTM)

INTIN/A

MRKRN/A

Forward P/S (NTM)

INTIN/A

MRKR3.16x

Revenue (TTM)

INTI$0

MRKR$2M

Revenue Growth (YoY)

INTIN/A

MRKR-46.2%

Forward Rev Growth

INTI0.0%

MRKR375.8%

Gross Margin (TTM)

INTI20.9%

MRKR0.0%

Operating Margin (TTM)

INTI0.0%

MRKR0.0%

EBITDA Margin (TTM)

INTI0.0%

MRKR-284.3%

Net Margin (TTM)

INTI0.0%

MRKR-236.6%

FCF Margin (TTM)

INTIN/A

MRKR-417.6%

Net Income (TTM)

INTI$-3M

MRKR$-6M

FCF (TTM)

INTI$-3M

MRKR$-10M

EPS (TTM)

INTI$0.00

MRKR-$0.27

ROE (TTM)

INTI-33792.0%

MRKR-8086.0%

ROA (TTM)

INTI-12210.0%

MRKR-6705.0%

ROIC (TTM)

INTI-33792.0%

MRKR-8086.0%

Cash

INTI$516K

MRKR$11M

Debt

INTI$0

MRKR$0

Net Cash/Debt

INTI$516K

MRKR$11M

Current Ratio (TTM)

INTI3.36x

MRKR6.03x

Quick Ratio (TTM)

INTI2.95x

MRKR5.60x

Debt/Equity (TTM)

INTI0.00x

MRKR0.00x

Debt/Assets (TTM)

INTI0.0%

MRKR0.0%

Interest Coverage (TTM)

INTIN/A

MRKRN/A

Net Debt/EBITDA (TTM)

INTI0.00x

MRKR0.00x

Beta

INTI-0.79

MRKR1.59

52W Performance

INTI127.9%

MRKR-10.0%

YTD Performance

INTI108.5%

MRKR-36.9%

% from 52W High

INTI-21.0%

MRKR-60.5%

% from 52W Low

INTI180.0%

MRKR15.7%

Asset Turnover (TTM)

INTI0.50x

MRKR0.20x

FCF Yield (TTM)

INTI-19.1%

MRKR-60.2%

Earnings Yield (TTM)

INTI-15.9%

MRKR-34.1%

Dividend Yield (TTM)

INTIN/A

MRKRN/A

Rule of 40

INTI0.0

MRKR-463.8

EV/GP/RG

INTIN/A

MRKRN/A

Ticker research

View INTI research View MRKR research

Metric	INTI Inhibitor Therapeutics Inc	MRKR Marker Therapeutics Inc
Market & Valuation
Market Cap	$17M	$16M
Enterprise Value	$16M	$5M
Price	$0.10	$0.97
P/E Ratio	N/A	N/A
P/S Ratio	4.25x	6.93x
EV/Sales	4.12x	2.08x
EV/EBITDA	1.61x	0.00x
P/B Ratio	4,922.43x	1.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.09x	-0.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.16x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	-46.2%
Forward Rev Growth	0.0%	375.8%
Profitability
Gross Margin (TTM)	20.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-284.3%
Net Margin (TTM)	0.0%	-236.6%
FCF Margin (TTM)	N/A	-417.6%
Net Income (TTM)	$-3M	$-6M
FCF (TTM)	$-3M	$-10M
EPS (TTM)	$0.00	-$0.27
ROE (TTM)	-33792.0%	-8086.0%
ROA (TTM)	-12210.0%	-6705.0%
ROIC (TTM)	-33792.0%	-8086.0%
Financial Health
Cash	$516K	$11M
Debt	$0	$0
Net Cash/Debt	$516K	$11M
Current Ratio (TTM)	3.36x	6.03x
Quick Ratio (TTM)	2.95x	5.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.79	1.59
52W Performance	127.9%	-10.0%
YTD Performance	108.5%	-36.9%
% from 52W High	-21.0%	-60.5%
% from 52W Low	180.0%	15.7%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.20x
FCF Yield (TTM)	-19.1%	-60.2%
Earnings Yield (TTM)	-15.9%	-34.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-463.8
EV/GP/RG	N/A	N/A
Ticker research	View INTI research	View MRKR research